Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy Volunteers

Inclusion criteria: Healthy subjects: * Male or female subject, healthy according to the investigator's judgement based on a complete medical history, including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory * Age of 18 to 79 years at screening visit Hepatically impaired patients as determined by a hepatologist/ gastroenterologist: * A documented diagnosis of the impaired hepatic function, determined by hepatologist/gastroenterologist/specialist for internal medicine, must be available in the patient´s source data. * Male or female chronic hepatically impaired patient as determined by screening results and classified as Child-Pugh A (Child-Pugh score of 5-6 points) or as Child-Pugh B (Child-Pugh score of 7-9 points). Hepatic insufficiency must be diagnosed at least 3 months before screening. * Age of 18 to 79 years at screening visit Exclusion criteria: Healthy subjects: * Any finding in the medical examination (including BP, PR or ECG) deviating from normal and judged as clinically relevant by the investigator * Any laboratory value outside the reference range at screening visit that the investigator considers to be of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders judged as clinically relevant by the investigator * Surgery of the gastrointestinal tract that could interfere with kinetics of the trial medication based on the investigator´s judgment * Women who are breast feeding or of child-bearing potential not using a highly effective method of birth control for at least one month prior to inclusion and at least 3 month after administration of trial medication. Hepatically impaired patients as determined by a hepatologist/gastroenterologist: * Medical disorder, condition or history of such that would impair the patient's ability to participate or complete this study in the opinion of the investigator or the sponsor * Patients with significant diseases other than underlying diagnose of hepatic impairment and concomitant diseases related to it. A significant disease is defined as a disease which in the opinion of the investigator: * put the patient at risk because of participation in the study * may influence the results of the study * is not in a stable condition * Surgery of the gastrointestinal tract that could interfere with the kinetics of the trial medication based on the investigator´s judgment * Women who are breast feeding or of child-bearing potential not using a highly effective method of birth control for at least one month prior to inclusion and at least 3 month after administration of trial medication